Moderna Just Proved Cancer Vaccines Work. Now Comes the Hard Part.
Moderna’s first positive Phase 3 for mRNA neoantigen therapy in melanoma is a historic breakthrough. But the real story isn’t the stock surge—it’s the platform’s potential to turn cancer into a chronic condition. The 90% clinical trial failure rate casts a long shadow, and the hardest part—scalability and cost—is just beginning.